National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Tisagenlecleucel (Kymriah®) for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.


NCPE Assessment Process Complete
Rapid review commissioned 19/09/2018
Rapid review completed 19/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/10/2018
Pre-submission consultation with Applicant 06/11/2018
Submission received from Applicant 30/01/2019
Preliminary review sent to Applicant 11/04/2019
NCPE assessment re-commenced 10/05/2019
Factual accuracy sent to Applicant 23/07/2019
NCPE assessment re-commenced 01/08/2019
NCPE assessment completed 27/08/2019
NCPE assessment outcome The NCPE recommends that tisagenlecleucel (Kymriah®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.